Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FO1-HP2H9 | Human | PE-Labeled Human FOLR1 Protein, His Tag (Site-specific conjugation) | ![]() |
![]() ![]() |
|
FO1-HF2H8 | Human | FITC-Labeled Human FOLR1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
FO1-H52H1 | Human | Human FOLR1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
FO1-H82F9 | Human | Biotinylated Human FOLR1 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
FO1-H5253 | Human | Human FOLR1 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
FO1-H82E2 | Human | Biotinylated Human FOLR1 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
FO1-C52H8 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque FOLR1 Protein, His tag | ![]() |
![]() ![]() |
![]() ![]() |
FO1-M82E9 | Mouse | Biotinylated Mouse FOLR1 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
FO1-M5225 | Mouse | Mouse FOLR1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
FO1-H528b | Human | Human FOLR1 Protein, Strep Tag | ![]() |
![]() ![]() |
![]() ![]() |
5e5 of anti-FOLR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human FOLR1, His Tag (Cat. No. FO1-HP2H9) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Folic Acid-BSA Conjugate at 5 μg/mL (100 μL/well) can bind Human FOLR1, His Tag (Cat. No. FO1-H52H1) with a linear range of 5-78 ng/mL (QC tested).
The purity of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.
Immobilized Folic acid-BSA conjugate at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) with a linear range of 0.078-1.25 μg/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Pafolacianine Sodium | Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 | Approved | On Target Laboratories Inc | Cytalux | United States | Ovarian Neoplasms | On Target Laboratories Inc | 2021-11-29 | Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms | Details |
Folinic Acid | FTHF | Approved | Colorectal Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CBP-1008 | CBP-1008 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Ovarian Neoplasms; Solid tumours; Breast Neoplasms; Carcinoma, Squamous Cell | Details |
Vintafolide | EC-145; MK-8109 | Phase 2 Clinical | Novartis Pharma Ag | Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Noscapine-folate conjugate | Phase 1 Clinical | Emory University | Hematologic Neoplasms; Inflammation | Details | |
4S-CAR-FRa | 4S-CAR-FRa | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Details |
MOv19-BBz CAR-T cells Therapy | Phase 1 Clinical | University Of Pennsylvania | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details | |
MOv-18 IgE | MOv-18 IgE | Phase 1 Clinical | King'S College London, Cancer Research Uk | Ovarian Neoplasms | Details |
Farletuzumab | MORAb-003 | Phase 3 Clinical | Morphotek | Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
MORAb-202 | MORAb-202 | Phase 2 Clinical | Eisai Co Ltd, Morphotek, Bristol-Myers Squibb Company | Solid tumours | Details |
STRO-002 | SP-7219; SP-7675; SP-7676; STRO-002; DBCO-Alexa647-conjugated SP7219 | Phase 1 Clinical | Sutro Biopharma | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Endometrioid | Details |
Arfolitixorin | ISO-901; 6R-MTHF | Phase 3 Clinical | Isofol Medical Ab | Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms | Details |
Mirvetuximab soravtansine | IMGN-853; M9346-Asulfo-SPDB-DM4 | Phase 3 Clinical | Immunogen Inc | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms | Details |
This web search service is supported by Google Inc.